Acceleron Pharma Inc. announced Matthew L. Sherman terminate and he will retire from his position as the Company's Executive Vice President and Chief Medical Officer and enter into a consulting agreement with the Company effective as of the first regular work day that is one week after the later of the date on which the Company publicly announces top line data for the Company's phase 3 clinical study with luspatercept known as the MEDALIST" Study or the date on which the Company publicly announces top line data from the phase 3 clinical study with luspatercept known as the BELIEVE Study.